VEGFA and age-related macular degeneration: Ranibizumab (Lucentis) was determined effective by two pivotal trials: the MARINA (minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD) and ANCHOR (anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularisation in AMD) trials.